We provide you with 20 years of free, institutional-grade data for VYGR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VYGR. Explore the full financial landscape of VYGR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Sandrock Alfred | Sale | -12,115 | $9.86 | $119,454 | 2024-04-03 |
| Ferguson Toby | Grant, award...etc | 105,000 | 2024-04-03 | ||
| Swartz Robin | Sale | -1,357 | $9.88 | $13,407 | 2024-04-03 |
| Swartz Robin | Sale | -3,966 | $7.45 | $29,547 | 2024-02-22 |
| Sandrock Alfred | Sale | -13,033 | $7.46 | $97,226 | 2024-02-22 |
| PFREUNDSCHUH PETER P. | Sale | -3,764 | $7.46 | $28,079 | 2024-02-22 |
| Carter Todd Alfred | Sale | -3,967 | $7.68 | $30,467 | 2024-02-22 |
| Fahey Sandell Jacquelyn | Grant, award...etc | 31,000 | 2024-02-16 | ||
| Swartz Robin | Grant, award...etc | 50,000 | 2024-02-16 | ||
| Sandrock Alfred | Grant, award...etc | 130,000 | 2024-02-16 | ||
| Carter Todd Alfred | Grant, award...etc | 38,500 | 2024-02-16 | ||
| PFREUNDSCHUH PETER P. | Grant, award...etc | 30,000 | 2024-02-16 | ||
| Swartz Robin | Sale | -2,543 | $7.15 | $18,182 | 2024-01-19 |
| Carter Todd Alfred | Sale | -1,266 | $7.18 | $9,090 | 2024-01-19 |
| PFREUNDSCHUH PETER P. | Sale | -13,567 | $6.99 | $94,833 | 2023-10-05 |
| Fahey Sandell Jacquelyn | Grant, award...etc | 61,000 | 2023-10-02 | ||
| Carter Todd Alfred | Sale | -10,500 | $8.16 | $85,680 | 2023-09-18 |
| Carter Todd Alfred | Derivatives Exercise | 5,000 | 2023-09-18 | ||
| Carter Todd Alfred | Sale | -5,500 | $10.8 | $59,400 | 2023-07-10 |
| Carter Todd Alfred | Sale | -5,000 | $11.41 | $57,050 | 2023-07-05 |
| Carter Todd Alfred | Derivatives Exercise | 5,000 | 2023-07-05 | ||
| Sandrock Alfred | Sale | -7,437 | $7.83 | $58,232 | 2023-04-05 |
| Swartz Robin | Sale | -1,259 | $7.83 | $9,858 | 2023-04-05 |
| Carter Todd Alfred | Sale | -2,193 | $7.76 | $17,018 | 2023-03-22 |
| Hesslein Robert W. | Sale | -4,410 | $7.76 | $34,222 | 2023-03-22 |
| Swartz Robin | Sale | -3,654 | $7.76 | $28,355 | 2023-03-22 |
| Swartz Robin | Sale | -15,373 | $8.2 | $126,059 | 2023-03-17 |
| Onyia Jude | Initial | 2023-02-27 | |||
| NEUROCRINE BIOSCIENCES INC | Open Market Purchase | 4,395,588 | $8.88 | 2023-02-24 | |
| PFREUNDSCHUH PETER P. | Grant, award...etc | 38,000 | 2023-02-22 | ||
| Hesslein Robert W. | Sale | -3,297 | $7.45 | $24,563 | 2023-02-22 |
| Carter Todd Alfred | Sale | -738 | $7.45 | $5,498 | 2023-02-22 |
| Carter Todd Alfred | Grant, award...etc | 34,000 | 2023-02-22 | ||
| Sandrock Alfred | Grant, award...etc | 120,000 | 2023-02-22 | ||
| Swartz Robin | Grant, award...etc | 40,000 | 2023-02-22 | ||
| Carter Todd Alfred | Sale | -797 | $7.67 | $6,113 | 2023-02-15 |
| Hesslein Robert W. | Sale | -2,868 | $7.67 | $21,998 | 2023-02-15 |
| Third Rock Ventures III, L.P. | Sale | -388,642 | $9.03 | $3,509,437 | 2023-02-01 |
| Third Rock Ventures III, L.P. | Sale | -50,000 | $9.02 | $451,000 | 2023-01-31 |
| Third Rock Ventures III, L.P. | Sale | -150,000 | $9.27 | $1,390,500 | 2023-01-26 |
| Third Rock Ventures III, L.P. | Sale | -155,000 | $9.15 | $1,418,250 | 2023-01-24 |
| Swartz Robin | Sale | -2,188 | $9.57 | $20,939 | 2023-01-19 |
| Hesslein Robert W. | Sale | -2,188 | $9.57 | $20,939 | 2023-01-19 |
| Carter Todd Alfred | Sale | -1,106 | $9.57 | $10,584 | 2023-01-19 |
| EcoR1 Capital, LLC | Sale | -902,400 | $7.67 | $6,922,942 | 2023-01-11 |
| Carter Todd Alfred | Sale | -388 | $6.41 | $2,487 | 2023-01-10 |
| Carter Todd Alfred | Grant, award...etc | 388 | $5.17 | 2023-01-10 | |
| PFREUNDSCHUH PETER P. | Grant, award...etc | 125,000 | 2022-10-04 | ||
| Carter Todd Alfred | Initial | 2022-09-21 | |||
| Third Rock Ventures III, L.P. | Sale | -349,972 | $6.09 | $2,131,329 | 2022-08-26 |
| Third Rock Ventures III, L.P. | Sale | -128,456 | $6.04 | $775,874 | 2022-08-18 |
| Third Rock Ventures III, L.P. | Sale | -483,815 | $6.12 | $2,960,948 | 2022-08-16 |
| Higgins Michael J | Sale | -13,891 | $6.7 | $93,070 | 2022-07-18 |
| PIERCE GLENN | Sale | -9,512 | $6.7 | $63,730 | 2022-07-18 |
| EcoR1 Capital, LLC | Open Market Purchase | 477,400 | $5.28 | 2022-06-23 | |
| Swartz Robin | Sale | -1,527 | $8.25 | $12,598 | 2022-04-06 |
| Hesslein Robert W. | Sale | -2,786 | $8.25 | $22,985 | 2022-04-06 |
| Swartz Robin | Sale | -4,413 | $8.29 | $36,584 | 2022-03-23 |
| Hesslein Robert W. | Sale | -4,955 | $8.29 | $41,077 | 2022-03-23 |
| Burek Julie | Sale | -2,649 | $8.29 | $21,960 | 2022-03-23 |
| Sandrock Alfred | Grant, award...etc | 100,000 | 2022-03-23 | ||
| Burek Julie | Sale | -789 | $3.55 | $2,801 | 2022-02-22 |
| Hesslein Robert W. | Sale | -4,100 | $3.55 | $14,555 | 2022-02-22 |
| Burek Julie | Sale | -361 | $3.36 | $1,213 | 2022-02-15 |
| Hesslein Robert W. | Sale | -3,252 | $3.36 | $10,927 | 2022-02-15 |
| Swartz Robin | Initial | 2022-02-09 | |||
| PIERCE GLENN | Grant, award...etc | 26,300 | 2022-01-18 | ||
| Burek Julie | Grant, award...etc | 10,000 | 2022-01-18 | ||
| Hesslein Robert W. | Grant, award...etc | 20,000 | 2022-01-18 | ||
| Higgins Michael J | Grant, award...etc | 45,205 | 2022-01-18 | ||
| Burek Julie | Sale | -3,328 | $2.83 | $9,418 | 2022-01-14 |
| Burek Julie | Grant, award...etc | 3,063 | $2.3 | 2022-01-14 | |
| Burek Julie | Initial | 2021-11-30 | |||
| Burek Julie | Grant, award...etc | 13,500 | 2021-11-30 |
The information provided in this report about VYGR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Voyager Therapeutics, Inc(NASDAQ:VYGR) 
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's ...
Website: http://www.voyagertherapeutics.com
Founded: 2013
Full Time Employees: 185
Sector: Healthcare
Industry: Biotechnology